Jill Ferry, PA
Physician Assistant · Harlan, IANPI 1588772685
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $998, 2.1 times the $484 reported in 2021. Among physician assistant clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 150 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$433
- Lilly USA, LLC$344
- AstraZeneca$241
- Bayer$223
- Pfizer$184
- Amgen$139
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,571100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $433 |
| Lilly USA, LLC | 20 | $344 |
| AstraZeneca(2 entities) | 15 | $241 |
| Bayer | 13 | $223 |
| Pfizer | 9 | $184 |
| Amgen | 10 | $139 |
| Novartis | 8 | $134 |
| Merck | 6 | $97 |
| Eisai Inc. | 4 | $86 |
| Boehringer Ingelheim | 4 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Vertex | 3 | $46 |
| Johnson & Johnson | 3 | $44 |
| AbbVie | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| Amarin Pharma, Inc. | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Biogen | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Abbott | 1 | $22 |
| Medtronic | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Seqirus USA Inc | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Bioxcel Therapeutics, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| GSK | 1 | $13 |
How this compares
$2,571 in reported general payments places this provider in the 90th percentile of 1,140 physician assistant providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 259 | $164,329 |
| OzempicSemaglutide | 134 | $112,900 |
| JardianceEmpagliflozin | 72 | $53,323 |
| XareltoRivaroxaban | 83 | $48,574 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $34,257 |
| RybelsusSemaglutide | 19 | $22,392 |
| FarxigaDapagliflozin Propanediol | 39 | $21,993 |
| JanuviaSitagliptin Phosphate | 47 | $20,192 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $13,778 |
| EntrestoSacubitril/Valsartan | 47 | $11,456 |
| MounjaroTirzepatide | 12 | $9,105 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $7,950 |
| Potassium Chloride | 375 | $7,286 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,607 |
| Levothyroxine Sodium | 777 | $6,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $184 | $164,329259 claims |
| Novo NordiskOzempic, Rybelsus | $433 | $135,293153 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $70 | $58,17783 claims |
| Johnson & JohnsonXarelto | $44 | $48,57483 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $13 | $47,04087 claims |
| AstraZenecaFarxiga | $241 | $21,99339 claims |
| MerckJanuvia | $97 | $20,19247 claims |
| NovartisEntresto | $134 | $11,45647 claims |
| Lilly USA, LLCMounjaro | $344 | $9,10512 claims |
| AbbVieSynthroid | $34 | $1,65226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,140 physician assistant providers in Iowa.
Other physician assistant in Harlan
- Shelby JohnsonHarlan$5K
- Jayson GesulgaUrbandale$878K
- Laurie ClairJohnston$293K
- Katherine LemAmes$224K
- Laura CunninghamWest Des Moines$128K
- Michon LeddyClive$73K
- Kyle HawkinsIowa City$42K
- Andrew MetzgerIowa City$37K
- Myrl HolidaIowa City$37K
- Kelly MerchieDavenport$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.